New drug IBI362 takes on semaglutide in fatty liver showdown
NCT ID NCT06884293
First seen May 18, 2026 · Last updated Jun 17, 2026 · Updated 5 times
Summary
This study tests whether a new weekly injection called IBI362 works better than the existing drug semaglutide for weight loss and reducing liver fat in overweight or obese Chinese adults with metabolic dysfunction-associated fatty liver disease (MAFLD). About 479 participants will receive either IBI362 or semaglutide for 48 weeks, followed by a 12-week safety check. The goal is to see which drug is more effective at helping people lose weight and lower fat in their liver.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.